版本:
中国

BRIEF-Rigel submits NDA to FDA for fostamatinib in chronic itp

April 17 Rigel Pharmaceuticals Inc:

* Rigel submits new drug application to fda for fostamatinib in chronic itp

* Rigel Pharmaceuticals Inc- company expects to receive notification regarding acceptance of NDA by FDA in June 2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐